Evidence map›Paper›PMID 26457026›Full record

ArticleWorld journal of gastroenterology2015

Plasma betatrophin levels in patients with liver cirrhosis.

Maria Teresa Arias-Loste, Maria Teresa García-Unzueta, Susana Llerena, Paula Iruzubieta, Angela Puente, Joaquín Cabezas, Carmen Alonso, Antonio Cuadrado, José Antonio Amado, Javier Crespo and 1 more

Abstract read
In one paragraph

Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maria Teresa Arias-LosteMaria Teresa Arias-Loste, Susana Llerena, Paula Iruzubieta, Angela Puente, Joaquín Cabezas, Carmen Alonso, Antonio Cuadrado, Javier Crespo, Emilio Fábrega, Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, Instituto de Investigación Sanitaria Valdecilla, Avenida Valdecilla s/n, 39008 Santander, Cantabria, Spain.
Maria Teresa García-UnzuetaMaria Teresa Arias-Loste, Susana Llerena, Paula Iruzubieta, Angela Puente, Joaquín Cabezas, Carmen Alonso, Antonio Cuadrado, Javier Crespo, Emilio Fábrega, Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, Instituto de Investigación Sanitaria Valdecilla, Avenida Valdecilla s/n, 39008 Santander, Cantabria, Spain.
Susana LlerenaMaria Teresa Arias-Loste, Susana Llerena, Paula Iruzubieta, Angela Puente, Joaquín Cabezas, Carmen Alonso, Antonio Cuadrado, Javier Crespo, Emilio Fábrega, Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, Instituto de Investigación Sanitaria Valdecilla, Avenida Valdecilla s/n, 39008 Santander, Cantabria, Spain.
Paula IruzubietaMaria Teresa Arias-Loste, Susana Llerena, Paula Iruzubieta, Angela Puente, Joaquín Cabezas, Carmen Alonso, Antonio Cuadrado, Javier Crespo, Emilio Fábrega, Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, Instituto de Investigación Sanitaria Valdecilla, Avenida Valdecilla s/n, 39008 Santander, Cantabria, Spain.
Angela PuenteMaria Teresa Arias-Loste, Susana Llerena, Paula Iruzubieta, Angela Puente, Joaquín Cabezas, Carmen Alonso, Antonio Cuadrado, Javier Crespo, Emilio Fábrega, Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, Instituto de Investigación Sanitaria Valdecilla, Avenida Valdecilla s/n, 39008 Santander, Cantabria, Spain.
Joaquín CabezasMaria Teresa Arias-Loste, Susana Llerena, Paula Iruzubieta, Angela Puente, Joaquín Cabezas, Carmen Alonso, Antonio Cuadrado, Javier Crespo, Emilio Fábrega, Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, Instituto de Investigación Sanitaria Valdecilla, Avenida Valdecilla s/n, 39008 Santander, Cantabria, Spain.
Carmen AlonsoMaria Teresa Arias-Loste, Susana Llerena, Paula Iruzubieta, Angela Puente, Joaquín Cabezas, Carmen Alonso, Antonio Cuadrado, Javier Crespo, Emilio Fábrega, Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, Instituto de Investigación Sanitaria Valdecilla, Avenida Valdecilla s/n, 39008 Santander, Cantabria, Spain.
Antonio CuadradoMaria Teresa Arias-Loste, Susana Llerena, Paula Iruzubieta, Angela Puente, Joaquín Cabezas, Carmen Alonso, Antonio Cuadrado, Javier Crespo, Emilio Fábrega, Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, Instituto de Investigación Sanitaria Valdecilla, Avenida Valdecilla s/n, 39008 Santander, Cantabria, Spain.
José Antonio AmadoMaria Teresa Arias-Loste, Susana Llerena, Paula Iruzubieta, Angela Puente, Joaquín Cabezas, Carmen Alonso, Antonio Cuadrado, Javier Crespo, Emilio Fábrega, Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, Instituto de Investigación Sanitaria Valdecilla, Avenida Valdecilla s/n, 39008 Santander, Cantabria, Spain.
Javier CrespoMaria Teresa Arias-Loste, Susana Llerena, Paula Iruzubieta, Angela Puente, Joaquín Cabezas, Carmen Alonso, Antonio Cuadrado, Javier Crespo, Emilio Fábrega, Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, Instituto de Investigación Sanitaria Valdecilla, Avenida Valdecilla s/n, 39008 Santander, Cantabria, Spain.
Emilio FábregaMaria Teresa Arias-Loste, Susana Llerena, Paula Iruzubieta, Angela Puente, Joaquín Cabezas, Carmen Alonso, Antonio Cuadrado, Javier Crespo, Emilio Fábrega, Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, Instituto de Investigación Sanitaria Valdecilla, Avenida Valdecilla s/n, 39008 Santander, Cantabria, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the plasma levels of betatrophin in patients with cirrhosis.

methodsForty patients diagnosed at the clinic with liver cirrhosis according to biological, ultrasonographic, or histological criteria were included. The severity of cirrhosis was classified according to Pugh's modification of Child's classification and MELD score. Insulin resistance (IR) was assessed by the Homeostasis Model Assessment. A total of 20 patients showed a MELD score higher than 14. The control group consisted in 15 sex-and aged-matched subjects. Fasting blood samples were obtained for subsequent analysis. Serum insulin was determined by Liaison automated immune chemiluminiscence assay (DiaSorin S.p.A.) using a sandwich assay. The sensitivity of the assay was 0.2 μU/mL. The intra and interassay variation coefficients were < 4% and < 10%, respectively. The normal values were between 2 and 17 μU/mL. Human active betatrophin was analyzed by specific quantitative sandwich ELISA (Aviscera Bioscience). The sensitivity of the assay was 0.4 ng/mL, and the intra and interassay reproducibility were < 6% and < 10%, respectively.

resultsPlasma betatrophin levels were significantly increased in patients with cirrhosis compared with those in healthy subjects (P = 0.0001). Betatrophin levels were also associated with disease severity, being higher in Child-Pugh C patients compared to Child-Pugh B (P < 0.0005) and in patients who displayed a MELD score higher than 14 points compared to patients with lower punctuation (P = 0.01). In addition, we found a positive correlation between plasma betatrophin levels and the severity of cirrhosis according to Child-Pugh classification (r = 0.53; P < 0.01) or MELD score (r = 0.45; P < 0.01). In the overall cohort, a moderate correlation between serum betatrophin and plasmatic bilirrubin (r = 0.39; P < 0.01) has been observed, as well as an inverse correlation between betatrophin and albumin (r = -0.41; P < 0.01) or prothrombin time (r = -0.44; P <0.01). Moreover, insulin resistance was observed in 82.5% of the cirrhotic patients. In this group of patients, betatrophin levels were significantly higher than those in the group of patients without IR (P < 0.05).

conclusionPlasma betatrophin is increased in patients with cirrhosis. This increase is related to the severity of cirrhosis, as well as with the emergence of insulin resistance.

Indexed as

AdultAgedAngiopoietin-Like Protein 8Angiopoietin-like ProteinsEnzyme-Linked Immunosorbent AssayFemaleHomeostasisHumansInsulin ResistanceLiver CirrhosisLuminescenceMaleMiddle AgedPeptide HormonesReproducibility of ResultsRetrospective StudiesAngiopoietin-Like Protein 8Angiopoietin-like ProteinsANGPTL8 protein, humanPeptide HormonesBetatrophinBetatrophin insulinBetatrophin liverInsulin resistanceLiver cirrhosis

Identifiers

PMID26457026
PMCPMC4588088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.